Glick H, Willke R, Polsky D, Llana T, Alves W M, Kassell N, Schulman K
University of Pennsylvania, USA.
Int J Technol Assess Health Care. 1998 Winter;14(1):145-60. doi: 10.1017/s026646230001059x.
This study used data from a multinational phase III randomized, double-blind, vehicle-controlled trial to evaluate the cost-effectiveness of tirilazad mesylate (Freedox) in the treatment of aneurysmal subarachnoid hemorrhage. In men, therapy with 6 mg/kg per day of tirilazad mesylate was associated with significantly increased survival, increased cost of care, and ratios of cost per death averted that compare favorably with the ratios of other life and death interventions. In women, it appeared to have no effects on costs or survival. Further clinical studies may provide additional information about the cost-effectiveness of this intervention.
本研究使用了一项跨国III期随机、双盲、载体对照试验的数据，以评估甲磺替拉扎特（弗里多克斯）治疗动脉瘤性蛛网膜下腔出血的成本效益。在男性中，每天6mg/kg甲磺替拉扎特治疗与生存率显著提高、护理成本增加以及每避免一例死亡的成本比率相关，该比率与其他生死干预措施的比率相比具有优势。在女性中，它似乎对成本或生存率没有影响。进一步的临床研究可能会提供有关这种干预措施成本效益的更多信息。
